Thalidomide in cancer treatment: A potential role in the elderly?

Drugs and Aging

Volumn 19, Issue 2, 2002, Pages 85-100

  Zhou, Shufeng ^a,c   Kestell, Philip ^b   Tingle, Malcolm D ^a   Paxton, James W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CYCLOPHOSPHAMIDE; MEGESTROL; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADENOCARCINOMA; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ELDERLY CARE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; MITOSIS INHIBITION; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RABBIT; RAT; REVIEW;

EID: 0036257544     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219020-00002     Document Type: Review

References (164)

1. Thalidomide and congenital abnormalities
2. Thalidomide and congenital abnormalities
3. Thalidomide is an inhibitor of angiogenesis
4. Thalidomide: A prodrug that inhibits angiogenesis
5. Novel biological response modifiers derived from thalidomide
6. Thalidomide: Current and potential clinical applications
7. Potential novel uses of thalidomide: Focus on palliative care
8. Thalidomide and analogs
9. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy
10. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodusum leprosum
11. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus
12. Treatment of refractory rheumatoid arthritis: The thalidomide experience
13. The role of thalidomide in the treatment of rheumatic disease
14. Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease
15. Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217)
16. Treatment of colitis in Behcet's disease with thalidomide
17. Potential new therapeutic options in Behcet's syndrome
18. Thalidomide for treatment of patients with chronic graft-versus-host disease
19. Thalidomide for the treatment of chronic graft-versus-host disease
20. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
21. Thalidomide inhibits the replication of human immunodeficiency virus type 1
22. Thalidomide: A novel therapy for microsporidiosis
23. Efficacy of long term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results
24. Treatment of severe esophageal Crohn's disease with thalidomide
25. Therapy for Crohn disease
26. Thalidomide treatment of oesophageal ulceration
27. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide
28. Enantiomers of thalidomide-blood distribution and the influence of serum albumin on chiral inversion and hydrolysis
29. Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man
30. A double-blind study of the sedative effects of the thalidomide enantiomers in humans
31. Enantioselective inhibition of TNF-α release by thalidomide and thalidomide analogues
32. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
33. Phase II evaluation of thalidomide in patients with metastatic breast cancer
34. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas
35. Phase II study of thalidomide as an anti-angiogenic agent in the treatment of recurrent glioblastoma multiforme (GBM)
36. Phase I trial of thalidomide in AIDS-related Kaposi sarcoma
37. Phase II trial of thalidomide in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCHN)
38. The rationale and future potential of angiogenesis inhibitors in neoplasia
39. 'Accidental' anti-angiogenic drugs: Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples
40. Thalidomide and chemotherapy combination: Preliminary results of preclinical and clinical studies
41. Tumor vasculature as a target for cancer therapy
42. Tumor angiogenesis: Past, present and the near future
43. Mechanisms of tumor angiogenesis and therapeutic implications: Angiogenesis inhibitors
44. Angiogenesis in cancer and other diseases
45. Tumor vasculature as a target for anticancer therapy
46. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
47. Antivascular therapy: A new approach to cancer treatment
48. Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent
49. Suppression of serum tumor necrosis factor-α by thalidomide does not lead to reversal of tumor vascular collapse and anti-tumor activity of 5,6-dimethylxanthenone-4-acetic acid
50. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
51. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice
52. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
53. The effect of thalidomide on experimental tumors and metastases
54. Hydroxylated metabolites of thalidomide: Formation in-vitro and in-vivo in man
55. Investigation of the stereoselective in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis
56. Investigation of the in vitro biotransformation of R-(+)-thalidomide by HPLC, nano-HPLC, CEC and HPLC-APCI-MS
57. Disposition of thalidomide in rabbits and rats
58. The metabolism of thalidomide and some of its hydrolysis products in various species
59. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen's disease patients
60. Investigation of the in vitro biotransformation and simultaneous separation of thalidomide and its neutral metabolites by capillary electrophoresis
61. Thalidomide teratogenesis: Evidence for a toxic arene oxide metabolite
62. Study of anti-angiogenic agents with possible therapeutic applications in neoplastic disorders and macular degeneration
63. Effects of hyperthermia and tumor necrosis factor on inflammatory cytokine secretion and procoagulant activity in endothelial cells
64. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis
65. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
66. Requirement of vascular integrin avb3 for angiogenesis
67. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
68. The role of av integrins during angiogenesis: Insights into potential mechanisms of action and clinical development
69. The role of vascular cell integrins α v β3 and α v β5 in angiogenesis
70. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
71. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation
72. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
73. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
74. Thalidomide as an anti-TNF-α inhibitor: Implications for clinical use
75. Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-α production
76. Cell-type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-α production and its enantio-dependence
77. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-α by mononuclear cells
78. Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide
79. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients
80. Inhibition of IL-12 production by thalidomide
81. Thalidomide's ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their blood
82. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative
83. Modulation of LPS-, PHA- and M-tuberculosis-mediated cytokine production by pentoxifylline and thalidomide
84. Immune stimulation in scleroderma patients treated with thalidomide
85. Theoretical basis for the activity of thalidomide
86. Management of Kaposi sarcoma: The role of interferon and thalidomide
87. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete γ interferon in healthy humans
88. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-α
89. Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice
90. Induction of apoptosis by cancer chemotherapy
91. Apoptosis and cancer chemotherapy
92. Effects of thalidomide on apoptosis of lymphocytes and neutrophils
93. Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro
94. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model
95. Cytokines as suppressors of apoptosis
96. Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug
97. A comparison of thalidomide and pentobarbitol: New methods for identifying novel hypnotic drugs
98. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients
99. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo
100. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma
101. Failure of thalidomide as an anti-angiogenesis factor in a murine melanoma model
102. Studies on the possible antineoplastic effect of thalidomide
103. Thalidomide: Influence on production of congenital abnormalities in mice and cancer chemotherapy
104. Preliminary studies on the interaction between cyclophosphamide and thalidomide
105. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: Relation to vascular effects
106. Stimulation of tumors to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
107. Induction of tumor necrosis factor-α by single and repeated doses of the antitumor agent 5,6-dimethylxanthenone-4-acetic acid
108. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid
109. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice
110. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumor agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumor necrosis factor-α and enhancement of anti-tumor activity
111. Effect of thalidomide on tumor necrosis factor production and anti-tumor activity induced by 5,6-dimethylxanthenone-4-acetic acid
112. Thalidomide increases both intra-tumoral tumor necrosis factor-α production and anti-tumor activity in response to 5,6-dimethylxanthenone-4-acetic acid
113. Modulation of the plasma pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid by thalidomide in mice
114. In vitro and in vivo kinetic interactions of the anti-tumor agent 5,6-dimethyxanthenone-4-acetic acid with thalidomide and diclofenac
115. Thalidomide promotes metastasis of prostate adenocarcinoma cells (PA-III) in L-W rats
116. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits
117. Teratogenic effect of N-phthalyl-DL-glutamic acid following intraperitoneal application in mice
118. Clinical experience with thalidomide in patients with cancer
119. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer
120. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation PBPC in patients with metastatic breast cancer
121. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
122. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC)
123. Pharmacokinetics of thalidomide in an elderly prostate cancer population
124. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titer
125. Activity of thalidomide in AIDS-related Kaposi's sarcoma
126. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches
127. A phase I/II study of carboplatin and thalidomide in recurrent glioblastoma multiforme
128. Thalidomide in hematologic malignancies: Futura directions
129. Thalidomide for resistant and relapsing myeloma
130. Thalidomide: Therapeutic potential in hematologic malignancies
131. Thalidomide treatment of resistant or relapsed multiple myeloma patients
132. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
133. Thalidomide in multiple myeloma
134. Therapy with thalidomide in refractory multiple myeloma patients: The revival of an old drug
135. Low-dose thalidomide seems to be effective in multiple myeloma
136. Thalidomide continues to look promising as an anticancer agent
137. Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies
138. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma
139. Thalidomide in the treatment of relapsed multiple myeloma
140. Antitumor activity of thalidomide in refractory multiple myeloma
141. Thalidomide: Near complete regression of extramedullary bulk in refractory multiple myeloma
142. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent
143. Effect of thalidomide on gastrointestinal toxic effects of irinotecan
144. Thalidomide treatment of metastatic renal cell carcinoma
145. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide
146. Pilot and safety trial of carboplatin, paclitaxel and thalidomide in advanced non-small cell lung cancer
147. Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders
148. The cancer anorexia-cachexia syndrome
149. The role of cytokines in cancer cachexia
150. Cancer anorexia-cachexia syndrome: Are neuropeptides the key?
151. Geriatric cachexia: The role of cytokines
152. Anticytokine approaches to the treatment of anorexia and cachexia
153. Thalidomide in patients with cachexia due to terminal cancer: Preliminary report
154. Thalidomide for night sweats in patients with advanced cancer
155. Thalidomide for distressing night sweats in advanced malignant disease
156. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
157. Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
158. Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites
159. Chemical structure and teratogenic properties. 3. A review of available data on structure-activity relationships and mechanism of action of thalidomide analogues
160. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α
161. Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: Potent inhibitors of tumor metastasis
162. Cytokine activity in cancer-related anorexia/cachexia: Role of megestrol acetate and medroxyprogesterone acetate